This atypical CLL score proposed in this study helped to offer an accurate differentiation of CLL from non‐CLL malignancies, particularly in CD5 or CD23‐negative mature B‐cell neoplasms with a clinical suspicion of CLL. The gene discussed is FCER2; the disease is B-cell neoplasm.